AAPL293.08-1.22 (-0.41%) ▼|ABBV234.89+0.13 (+0.06%) ▲|ABT90.49-0.04 (-0.04%) ▼|ACN129.15+2.14 (+1.68%) ▲|ADBE196.57-0.86 (-0.44%) ▼|AMAT588.97+3.09 (+0.53%) ▲|AMD519.74-0.11 (-0.02%) ▼|AMGN351.43+4.42 (+1.27%) ▲|AMT174.46-4.92 (-2.74%) ▼|AMZN234.27+0.16 (+0.07%) ▲|AVGO382.07+1.92 (+0.51%) ▲|AXP342.56+4.78 (+1.42%) ▲|BA220.25+3.54 (+1.63%) ▲|BAC57.73-0.18 (-0.31%) ▼|BKNG181.25+12.31 (+7.29%) ▲|BLK982.60-32.73 (-3.22%) ▼|BMY55.00-0.53 (-0.95%) ▼|BNY143.56-3.73 (-2.53%) ▼|BRK-B494.81+2.00 (+0.41%) ▲|C143.59-1.38 (-0.95%) ▼|CAT994.45+10.21 (+1.04%) ▲|CL91.88+0.45 (+0.49%) ▲|CMCSA22.64-0.16 (-0.70%) ▼|COF200.48+2.67 (+1.35%) ▲|COP106.92-3.05 (-2.77%) ▼|COST961.09+3.41 (+0.36%) ▲|CRM152.76-0.66 (-0.43%) ▼|CSCO119.73-1.42 (-1.17%) ▼|CVS101.87+0.30 (+0.30%) ▲|CVX171.45-4.53 (-2.57%) ▼|DE600.75+8.81 (+1.49%) ▲|DHR188.87+9.90 (+5.53%) ▲|DIS101.12-2.41 (-2.33%) ▼|DUK126.53+1.48 (+1.18%) ▲|EMR141.44-1.70 (-1.19%) ▼|FDX316.83-0.41 (-0.13%) ▼|GD344.32-6.02 (-1.72%) ▼|GE365.88+9.41 (+2.64%) ▲|GEV1,057.65+22.67 (+2.19%) ▲|GILD125.16+0.11 (+0.09%) ▲|GM78.95+0.00 (+0.00%) ▲|GOOG345.04-1.04 (-0.30%) ▼|GOOGL345.29-0.80 (-0.23%) ▼|GS1,076.91-17.53 (-1.60%) ▼|HD342.86+18.41 (+5.67%) ▲|HON227.42+5.05 (+2.27%) ▲|IBM262.96-1.98 (-0.75%) ▼|INTC131.65-0.63 (-0.48%) ▼|INTU262.24+4.19 (+1.62%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ241.00+1.92 (+0.80%) ▲|JPM333.45-0.69 (-0.21%) ▼|KO80.60+0.29 (+0.36%) ▲|LIN515.73+3.47 (+0.68%) ▲|LLY1,117.26+10.18 (+0.92%) ▲|LMT491.64-12.03 (-2.39%) ▼|LOW221.45+7.91 (+3.70%) ▲|LRCX374.80+3.47 (+0.93%) ▲|MA494.41+6.34 (+1.30%) ▲|MCD273.88+2.22 (+0.82%) ▲|MDLZ61.74+0.68 (+1.11%) ▲|MDT80.13-0.50 (-0.62%) ▼|META557.67-4.53 (-0.81%) ▼|MMM165.91+4.07 (+2.51%) ▲|MO72.07+0.46 (+0.64%) ▲|MRK120.60+1.00 (+0.84%) ▲|MS219.86-6.17 (-2.73%) ▼|MSFT365.46-8.48 (-2.27%) ▼|MU1,048.51-3.26 (-0.31%) ▼|NEE87.62+1.19 (+1.38%) ▲|NFLX71.84-0.98 (-1.35%) ▼|NKE41.82-0.56 (-1.32%) ▼|NOW93.80-2.14 (-2.23%) ▼|NVDA199.00-1.00 (-0.50%) ▼|ORCL157.53-7.63 (-4.62%) ▼|PEP142.27+0.22 (+0.15%) ▲|PFE24.04-0.68 (-2.75%) ▼|PG152.04+1.18 (+0.78%) ▲|PLTR113.50-3.20 (-2.74%) ▼|PM178.78+0.09 (+0.05%) ▲|QCOM197.41-6.72 (-3.29%) ▼|RTX185.06-1.33 (-0.71%) ▼|SBUX103.53+2.48 (+2.45%) ▲|SCHW91.39-1.78 (-1.91%) ▼|SO95.78+0.85 (+0.90%) ▲|SPG222.15+5.41 (+2.50%) ▲|T22.37-0.44 (-1.93%) ▼|TMO492.20+22.85 (+4.87%) ▲|TMUS180.79-3.78 (-2.05%) ▼|TSLA375.53-6.08 (-1.59%) ▼|TXN303.11-1.25 (-0.41%) ▼|UBER73.85+4.18 (+6.00%) ▲|UNH405.80-3.45 (-0.84%) ▼|UNP259.96+1.35 (+0.52%) ▲|UPS106.14+0.31 (+0.29%) ▲|USB60.11+0.06 (+0.10%) ▲|V332.23+3.75 (+1.14%) ▲|VZ45.68-1.05 (-2.25%) ▼|WFC84.30+0.17 (+0.20%) ▲|WMT119.00-0.42 (-0.35%) ▼|XOM136.90-2.83 (-2.03%) ▼|AAPL293.08-1.22 (-0.41%) ▼|ABBV234.89+0.13 (+0.06%) ▲|ABT90.49-0.04 (-0.04%) ▼|ACN129.15+2.14 (+1.68%) ▲|ADBE196.57-0.86 (-0.44%) ▼|AMAT588.97+3.09 (+0.53%) ▲|AMD519.74-0.11 (-0.02%) ▼|AMGN351.43+4.42 (+1.27%) ▲|AMT174.46-4.92 (-2.74%) ▼|AMZN234.27+0.16 (+0.07%) ▲|AVGO382.07+1.92 (+0.51%) ▲|AXP342.56+4.78 (+1.42%) ▲|BA220.25+3.54 (+1.63%) ▲|BAC57.73-0.18 (-0.31%) ▼|BKNG181.25+12.31 (+7.29%) ▲|BLK982.60-32.73 (-3.22%) ▼|BMY55.00-0.53 (-0.95%) ▼|BNY143.56-3.73 (-2.53%) ▼|BRK-B494.81+2.00 (+0.41%) ▲|C143.59-1.38 (-0.95%) ▼|CAT994.45+10.21 (+1.04%) ▲|CL91.88+0.45 (+0.49%) ▲|CMCSA22.64-0.16 (-0.70%) ▼|COF200.48+2.67 (+1.35%) ▲|COP106.92-3.05 (-2.77%) ▼|COST961.09+3.41 (+0.36%) ▲|CRM152.76-0.66 (-0.43%) ▼|CSCO119.73-1.42 (-1.17%) ▼|CVS101.87+0.30 (+0.30%) ▲|CVX171.45-4.53 (-2.57%) ▼|DE600.75+8.81 (+1.49%) ▲|DHR188.87+9.90 (+5.53%) ▲|DIS101.12-2.41 (-2.33%) ▼|DUK126.53+1.48 (+1.18%) ▲|EMR141.44-1.70 (-1.19%) ▼|FDX316.83-0.41 (-0.13%) ▼|GD344.32-6.02 (-1.72%) ▼|GE365.88+9.41 (+2.64%) ▲|GEV1,057.65+22.67 (+2.19%) ▲|GILD125.16+0.11 (+0.09%) ▲|GM78.95+0.00 (+0.00%) ▲|GOOG345.04-1.04 (-0.30%) ▼|GOOGL345.29-0.80 (-0.23%) ▼|GS1,076.91-17.53 (-1.60%) ▼|HD342.86+18.41 (+5.67%) ▲|HON227.42+5.05 (+2.27%) ▲|IBM262.96-1.98 (-0.75%) ▼|INTC131.65-0.63 (-0.48%) ▼|INTU262.24+4.19 (+1.62%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ241.00+1.92 (+0.80%) ▲|JPM333.45-0.69 (-0.21%) ▼|KO80.60+0.29 (+0.36%) ▲|LIN515.73+3.47 (+0.68%) ▲|LLY1,117.26+10.18 (+0.92%) ▲|LMT491.64-12.03 (-2.39%) ▼|LOW221.45+7.91 (+3.70%) ▲|LRCX374.80+3.47 (+0.93%) ▲|MA494.41+6.34 (+1.30%) ▲|MCD273.88+2.22 (+0.82%) ▲|MDLZ61.74+0.68 (+1.11%) ▲|MDT80.13-0.50 (-0.62%) ▼|META557.67-4.53 (-0.81%) ▼|MMM165.91+4.07 (+2.51%) ▲|MO72.07+0.46 (+0.64%) ▲|MRK120.60+1.00 (+0.84%) ▲|MS219.86-6.17 (-2.73%) ▼|MSFT365.46-8.48 (-2.27%) ▼|MU1,048.51-3.26 (-0.31%) ▼|NEE87.62+1.19 (+1.38%) ▲|NFLX71.84-0.98 (-1.35%) ▼|NKE41.82-0.56 (-1.32%) ▼|NOW93.80-2.14 (-2.23%) ▼|NVDA199.00-1.00 (-0.50%) ▼|ORCL157.53-7.63 (-4.62%) ▼|PEP142.27+0.22 (+0.15%) ▲|PFE24.04-0.68 (-2.75%) ▼|PG152.04+1.18 (+0.78%) ▲|PLTR113.50-3.20 (-2.74%) ▼|PM178.78+0.09 (+0.05%) ▲|QCOM197.41-6.72 (-3.29%) ▼|RTX185.06-1.33 (-0.71%) ▼|SBUX103.53+2.48 (+2.45%) ▲|SCHW91.39-1.78 (-1.91%) ▼|SO95.78+0.85 (+0.90%) ▲|SPG222.15+5.41 (+2.50%) ▲|T22.37-0.44 (-1.93%) ▼|TMO492.20+22.85 (+4.87%) ▲|TMUS180.79-3.78 (-2.05%) ▼|TSLA375.53-6.08 (-1.59%) ▼|TXN303.11-1.25 (-0.41%) ▼|UBER73.85+4.18 (+6.00%) ▲|UNH405.80-3.45 (-0.84%) ▼|UNP259.96+1.35 (+0.52%) ▲|UPS106.14+0.31 (+0.29%) ▲|USB60.11+0.06 (+0.10%) ▲|V332.23+3.75 (+1.14%) ▲|VZ45.68-1.05 (-2.25%) ▼|WFC84.30+0.17 (+0.20%) ▲|WMT119.00-0.42 (-0.35%) ▼|XOM136.90-2.83 (-2.03%) ▼|
20.6 C
New York
Thursday, June 25, 2026

Tag: coverage

Vooglam Brings Immersive Eyewear Experience to Electric Forest with Cult Vision Collection

AUSTIN, Texas, June 22, 2025 /PRNewswire/ -- Eyewear brand Vooglam will elevate festival style to new heights at Electric Forest, taking place from June...

Connecting Care with Clicks 2025 Draws Full House of Healthcare Leaders to Kuala Lumpur for One-Day Innovation Summit

KUALA LUMPUR, Malaysia, June 23, 2025 /PRNewswire/ -- Healthcare professionals, policy leaders, and digital health innovators gathered for Connecting Care with Clicks 2025 (CCC 2025),...

Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)

SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data...

Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors1. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C.

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated...

Revolutionary Research by Dr. Takuma Hayashi Uncovers Molecular Origins of Deadly Uterine Cancer and Charts New Path for Treatment

In a landmark advancement for women's cancer research, Dr. Takuma Hayashi and his team have made groundbreaking discoveries that could transform our understanding and...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Insurers Suddenly Discover Compassion—Expect a Fine Print Frenzy

As if the insurance industry needed another reminder that it's universally adored, the titans of health coverage are slinking back from their beloved pastime...

Tigé Boats, Inc. Debuts Fully Redesigned Z3 for 2026

ABILENE, Texas, June 20, 2025 /PRNewswire/ -- Tigé Boats, Inc. is proud to release the all-new 2026 Z3. Representing the third generation of Tigé's...

NextEra Energy to meet with investors throughout June

JUNO BEACH, Fla., June 20, 2025 /PRNewswire/ -- NextEra Energy, Inc. (NYSE: NEE) today announced that members of the senior management team will participate...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCoverage